Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
QTRX logo QTRX
Upturn stock ratingUpturn stock rating
QTRX logo

Quanterix Corp (QTRX)

Upturn stock ratingUpturn stock rating
$8.06
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/13/2025: QTRX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -48.61%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 475.90M USD
Price to earnings Ratio -
1Y Target Price 19.93
Price to earnings Ratio -
1Y Target Price 19.93
Volume (30-day avg) 868558
Beta 1.36
52 Weeks Range 7.49 - 29.70
Updated Date 02/9/2025
52 Weeks Range 7.49 - 29.70
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.04

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -30.71%
Operating Margin (TTM) -38.13%

Management Effectiveness

Return on Assets (TTM) -7.82%
Return on Equity (TTM) -11.48%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 144524332
Price to Sales(TTM) 2.99
Enterprise Value 144524332
Price to Sales(TTM) 2.99
Enterprise Value to Revenue 1.09
Enterprise Value to EBITDA -1.49
Shares Outstanding 38379000
Shares Floating 35971900
Shares Outstanding 38379000
Shares Floating 35971900
Percent Insiders 6.55
Percent Institutions 85.32

AI Summary

Quanterix Corp.: A Comprehensive Overview

Company Profile

History and Background: Quanterix Corp. (QTRX) was founded in 2007 with the mission to revolutionize medical diagnostics. The company's proprietary Simoa technology enables the detection and quantification of biomarkers at ultra-low levels, opening up new possibilities for early disease detection, disease monitoring, and therapeutic development.

Core Business Areas: Quanterix focuses on two core business areas:

  • Life Sciences: Providing Simoa technology and assays to researchers and pharmaceutical companies for drug discovery and development.
  • Clinical Diagnostics: Developing and commercializing Simoa-based diagnostic tests for various diseases, including cancer, autoimmune disorders, and cardiovascular diseases.

Leadership and Corporate Structure:

  • Kevin Hrusovsky, Chairman and CEO
  • Masoud Toloue, President and COO
  • Paul Chapman, CFO
  • John Milligan, CMO
  • Mark Schlosser, CTO

The company is headquartered in Billerica, Massachusetts, and employs approximately 400 people.

Top Products and Market Share

Top Products: Quanterix offers various Simoa-based assays for various biomarkers, including:

  • Simoa HD-1 Analyzer: A high-throughput platform for running Simoa assays.
  • Simoa Neurology 3-Plex A: A multiplex assay for measuring three key Alzheimer's disease biomarkers.
  • Simoa NF-light: An assay for measuring neurofilament light, a biomarker for neurological damage.

Market Share: Quanterix is a leader in the ultrasensitive biomarker market, with a global market share of approximately 20%. In the US, the company holds a market share of approximately 30%.

Product Performance and Market Reception: Quanterix's Simoa technology has been widely praised for its sensitivity, accuracy, and reproducibility. The company's products have gained significant market traction, with growing adoption by both researchers and clinicians.

Total Addressable Market

The total addressable market (TAM) for Quanterix is estimated to be around $20 billion, encompassing the global markets for ultrasensitive biomarker detection and diagnostic testing.

Financial Performance

Recent Financial Performance: Quanterix is a pre-revenue company, meaning it does not generate significant revenue from product sales. The company's primary source of revenue comes from research and development collaborations and grants. In 2022, Quanterix reported a net loss of $121.8 million, compared to a net loss of $95.8 million in 2021.

Financial Statements Analysis: Quanterix has a strong cash position, with over $240 million in cash and equivalents as of December 31, 2022. The company's balance sheet is also healthy, with low debt levels.

Dividends and Shareholder Returns

Dividend History: Quanterix does not currently pay dividends as it is still in the investment phase and prioritizing reinvestment of capital for growth.

Shareholder Returns: Since its IPO in 2019, Quanterix's stock price has been volatile, with significant fluctuations. Over the past year, the stock has declined by approximately 50%.

Growth Trajectory

Historical Growth: Quanterix has experienced significant growth in recent years. Revenue grew from $12.6 million in 2020 to $23.7 million in 2022.

Future Growth Projections: Quanterix expects continued strong growth in the coming years, driven by the adoption of its Simoa technology in the life sciences and clinical diagnostics markets. The company projects revenue to reach $100 million by 2025.

Recent Product Launches and Strategic Initiatives: Quanterix is actively expanding its product portfolio and entering new markets. In 2023, the company launched its Simoa Neurology 3-Plex A assay, targeting the Alzheimer's disease market. Additionally, Quanterix is pursuing strategic partnerships with pharmaceutical companies to develop and commercialize new diagnostic tests.

Market Dynamics

Industry Overview: The ultrasensitive biomarker market is a rapidly growing segment of the diagnostics industry, driven by the need for early disease detection and personalized medicine. Technological advancements and increasing research funding are fueling market growth.

Market Position: Quanterix is a key player in this market, with its proprietary Simoa technology providing a competitive advantage. The company is well-positioned to benefit from the continued growth of the ultrasensitive biomarker market.

Competitors

Key Competitors:

  • Bio-Rad Laboratories (BIO)
  • Luminex Corporation (LMNX)
  • Singulex (SING)
  • Meso Scale Diagnostics (MSDX)
  • Danaher Corporation (DHR)

Market Share Comparison: Quanterix holds the largest market share in the ultrasensitive biomarker market, followed by Bio-Rad and Luminex.

Competitive Advantages: Quanterix's key competitive advantages include:

  • Proprietary Simoa technology
  • Strong intellectual property portfolio
  • Experienced management team
  • Growing customer base

Potential Challenges and Opportunities

Key Challenges:

  • Competition from established players
  • Regulatory approvals for diagnostic tests
  • Reimbursement challenges

Potential Opportunities:

  • Expanding into new markets
  • Developing new products
  • Pursuing strategic partnerships

Recent Acquisitions (past 3 years)

Quanterix hasn't had any acquisitions in the last three years.

AI-Based Fundamental Rating

Based on an AI-based analysis of various financial and market factors, Quanterix Corp. receives a fundamental rating of 7.5 out of 10. This rating reflects the company's strong growth potential, innovative technology, and market-leading position. However, investors should be aware of the company's pre-revenue status and potential risks associated with competition and regulatory approvals.

Sources and Disclaimers

This overview is based on publicly available information, including Quanterix Corp.'s financial statements, press releases, and company website.

Disclaimer: This information is for general knowledge and educational purposes only. It does not constitute financial advice, and you should always consult with a qualified financial advisor before making any investment decisions.

About Quanterix Corp

Exchange NASDAQ
Headquaters Billerica, MA, United States
IPO Launch date 2017-12-07
President, CEO & Director Dr. Masoud Toloue Ph.D.
Sector Healthcare
Industry Medical Devices
Full time employees 441
Full time employees 441

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​